Overall rank by patents
#30,381
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Teneobio, Inc.
USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
9
Total patents granted
3
CPC technology areas
27.6
Avg claims per patent
-
5-year filing velocity
The verdict
Teneobio holds 9 US patents across 3 technology areas, rank #30,381 of 50,000 tracked assignees.
- #30,381
- of 50,000 US assignees by volume
- Top 15%
- by Innovation Score (49.1/100)
- 27.6
- avg claims per patent
Portfolio overview
Teneobio, Inc. has been granted 9 US utility patents between 2022 and 2025, placing Teneobio, Inc. at rank #30,381 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 27.6 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, Teneobio, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Teneobio sits between Telit Communications S.p.a. (9 patents, rank #30,377) and Test Rite International Co., Ltd. (9 patents, rank #30,385) - the closest US assignees by grant volume. The composite Innovation Score of 49.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Teneobio, Inc.'s 27.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Teneobio, Inc. against peers pursuing similar technology classes.
Who files at Teneobio's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Telit Communicati…
Telit Communications S.p.A.
9 patents
- Telling Industries
Telling Industries, LLC
9 patents
- Tempus Ex Machina
Tempus Ex Machina, Inc.
9 patents
- Tenaris Connectio…
Tenaris Connections Limited
9 patents
- Terran Biosciences
Terran Biosciences Inc.
9 patents
- Tescan Brno s r o
Tescan Brno s.r.o.
9 patents
- Tesseract Health
Tesseract Health, Inc.
9 patents
- Test Rite Interna…
Test Rite International Co., Ltd.
9 patents
- Teneobio ◀
TeneoBio, Inc.
9 patents
What this shows Teneobio holds 9 patents at rank #30,381, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Teneobio
By rank, the assignees closest to #30,381 in granted patent volume.
- Telit Communications S.p.a. #30,377 · 9 patents
- Telling Industries, Llc #30,378 · 9 patents
- Tempus Ex Machina, Inc. #30,379 · 9 patents
- Tenaris Connections Limited #30,380 · 9 patents
- Terran Biosciences Inc. #30,382 · 9 patents
- Tescan Brno S.r.o. #30,383 · 9 patents
- Tesseract Health, Inc. #30,384 · 9 patents
- Test Rite International Co., Ltd. #30,385 · 9 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Teneobio's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Teneobio's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 2 | 22.2% |
| 2023 | 1 | 11.1% |
| 2024 | 5 | 55.6% |
| 2025 | 1 | 11.1% |
Which technologies does Teneobio, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Teneobio, Inc. hold?
Teneobio, Inc. holds 9 US granted patents filed between 2022 and 2025, spanning 3 technology areas.
What is Teneobio, Inc.'s Innovation Score?
Teneobio, Inc. has an Innovation Score of 49.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Teneobio, Inc. focus on?
Teneobio, Inc.'s top technology area is C07K (PEPTIDES) with 9 patents. The company has filed patents in 3 CPC subclasses total.
Is Teneobio, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Teneobio, Inc..
What does claim depth mean for Teneobio, Inc.'s patents?
Teneobio, Inc.'s patents average 27.6 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Teneobio, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Teneobio's 9 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Teneobio ranks #30,381 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.